GlassScriptPhysician profile
David Michael Byrens
NPI 1902874126
$7,094.80
in general payments reported to CMS, 2019-2025
52 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,040 · 2020: $1,545 · 2021: $2,121 · 2022: $1,287 · 2023: $1,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,101.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $577.00 | 2019-2023 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $560.31 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $396.69 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $387.92 | 2019-2023 | |
| Lilly USA, LLC | $372.90 | 2019-2023 | Mounjaro, Trulicity |
| Novo Nordisk INC | $370.24 | 2019-2023 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $354.10 | 2020-2023 | Vaxneuvance, Gardasil 9, Vaxelis |
| Takeda Pharmaceuticals U.S.A., INC. | $318.29 | 2019-2023 | Gattex |
| Allergan, INC. | $317.78 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $306.74 | 2019-2023 | Jardiance, Tradjenta, Synjardy |
| Amarin Pharma, INC. | $291.89 | 2019-2021 | |
| Glaxosmithkline, LLC. | $267.75 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Nestle Healthcare Nutrition INC. | $234.72 | 2021-2023 | |
| Jazz Pharmaceuticals INC. | $187.11 | 2019-2021 | |
| Astellas Pharma US INC | $173.84 | 2020-2021 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Byrens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.